Lorena Taricani - Concepedia

Author

Lorena Taricani

Queen's University

Also Known As

L. Taricani, Lorena Taricani

109

Publications

588

Citations

H-Index

Concepts

All Affiliations

Queen's University Merck & Co., Inc., Rahway, NJ, USA (United States)Novartis (United States)Northwestern University

About

Lorena Taricani is an author at Queen's University specializing in natural sciences, medicine, and molecular biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	177
2	Natural Sciences	7	7	177
3	Biochemistry	4	4	101
4	Cell Biology	3	3	76
5	Chemical Biology	2	2	37

Lorena Taricani

Publications

578

Citations

H-Index

Page 1

	Year	Citations
Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer, Molecular Cancer Therapeutics	2011	170
A Synthetic Lethal Screen Reveals Enhanced Sensitivity to ATR Inhibitor Treatment in Mantle Cell Lymphoma with ATM Loss-of-Function Daniel L. Menezes, Jenny Holt, Yan Tang, Molecular Cancer Research	2014	99
Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-<i>a</i>]pyrazines as ATR Inhibitors Paul A. Barsanti, Robert J. Aversa, Xianming Jin, ACS Medicinal Chemistry Letters Pharmaceutical ScienceDrug TargetNovel PotentPharmacotherapyAtr Inhibitors	2014	41
Expression of hsp16 in response to nucleotide depletion is regulated via the spc1 MAPK pathway in Schizosaccharomyces pombe Lorena Taricani Nucleic Acids Research	2001	40
Replication stress activates DNA polymerase alpha-associated Chk1 Lorena Taricani, David Parry Cell Cycle ChromatinGenome InstabilityTranscriptional RegulationCell RegulationNatural Sciences	2009	39
The Fission Yeast ES2 Homologue, Bis1, Interacts with the Ish1 Stress-responsive Nuclear Envelope Protein Lorena Taricani, Max L. Tejada, Paul G. Young Journal of Biological Chemistry	2002	35
Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors Paul A. Barsanti, Yue Pan, Yipin Lu, ACS Medicinal Chemistry Letters Pharmaceutical ScienceDrug TargetIndole MoietyPharmacotherapyCompound 13	2014	27
Anti-Vpr Activity of a Yeast Chaperone Protein Zsigmond Benkő, Dong Liang, Emmanuel Agbottah, Journal of Virology	2004	26
Phenotypic enhancement of thymidylate synthetase pathway inhibitors following ablation of Neil1 DNA glycosylase/lyase Lorena Taricani, Rob H. Pierce, Timothy J. Guzi, Cell Cycle Molecular BiologyPhenotypic EnhancementCancer BiologyEnzymatic ModificationTumor Biology	2010	23
Rad4<sup>TopBP1</sup>, a Scaffold Protein, Plays Separate Roles in DNA Damage and Replication Checkpoints and DNA Replication Lorena Taricani, Teresa S.‐F. Wang Molecular Biology of the Cell ChromatinGenome InstabilityDna DamageBrct Domain ProteinNatural Sciences	2006	23

Page 1